-
AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results
19 Apr 2024 15:46 GMT
… February of this year, AstraZeneca’s Tagrisso received US Food … Tagrisso was directly compared to AstraZeneca’s Iressa, the first EGFRm … results showed a clear benefit with Tagrisso over its competitor … by 2030.
With clear benefits over first- and second- …
-
AstraZeneca's Alexion takes NMOSD awareness campaign long-form in new film highlighting community
18 Apr 2024 18:47 GMT
… neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit has … , the film had the added benefit of “giving voice to people …
-
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
17 Apr 2024 19:12 GMT
… registered trademark of Amgen and AstraZeneca Plc AZN.
Overall, tezepelumab numerically … /μL, potentially offering greater benefits than Dupixent for this subset …
-
AstraZeneca’s Imfinzi shows overall survival benefit in Phase III BTC trial
17 Apr 2024 11:00 GMT
… overall survival (OS) benefit in advanced biliary tract … with extended follow-up.
AstraZeneca Oncology research and development … showing a remarkable survival benefit for Imfinzi added to … .”
Earlier this month, AstraZeneca reported positive results from …
-
TOPAZ─1 phase III trial shows AstraZeneca's Imfinzi plus chemotherapy doubled OS rate at three years for patients with advanced biliary tract cancer
17 Apr 2024 03:44 GMT
… results reinforce the long-term benefit of this immunotherapy-based combination … cancer, showing a remarkable survival benefit for Imfinzi added to chemotherapy … jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Lynparza (olaparib …
-
Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer
16 Apr 2024 17:14 GMT
… showing a remarkable survival benefit for [durvalumab] added to … believe the significant survival benefit demonstrated marks a … reinforce the long-term benefit of this immunotherapy-based … interim analysis. News release. AstraZeneca. October 25, 2021. Accessed …
-
Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer
16 Apr 2024 17:00 GMT
… DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline … trial and error. Alongside their benefits, these drugs may come with … -Depressant Drugs Companies
AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline …
-
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
16 Apr 2024 13:12 GMT
AstraZeneca Plc AZN released updated … -term overall survival (OS) benefit in advanced biliary tract cancer … Hope for Aggressive Lung Cancer: AstraZeneca’s Imfinzi Shows Promising Results … chemotherapy alone.
Read Next: AstraZeneca Hikes Annual Dividend By 7% …
-
AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer
16 Apr 2024 11:40 GMT
AstraZeneca (AZ) has shared positive three- … BTC, showing a remarkable survival benefit for Imfinzi added to chemotherapy … results reinforce the long-term benefit of this immunotherapy-based combination …
-
The Hypocrisy and Facts of the United States Foreign Aid
20 Apr 2024 12:22 GMT
… ’ internal affairs for its own benefits, U.S. foreign aid brings … .. In 2022, 191,000 expiring AstraZeneca Covid-19 vaccines were rejected … first, advocating amity, sincerity, mutual benefit and inclusiveness are the unchanging …